Intech Investment Management LLC Sells 66,221 Shares of DexCom, Inc. $DXCM

Intech Investment Management LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 44.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 82,716 shares of the medical device company’s stock after selling 66,221 shares during the period. Intech Investment Management LLC’s holdings in DexCom were worth $5,566,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after buying an additional 1,133,638 shares during the period. Geode Capital Management LLC increased its stake in shares of DexCom by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after acquiring an additional 358,617 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after buying an additional 3,410,858 shares during the period. Norges Bank bought a new stake in shares of DexCom in the second quarter worth about $453,279,000. Finally, Groupama Asset Managment raised its position in shares of DexCom by 79,043.1% during the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after purchasing an additional 4,011,438 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DXCM opened at $73.43 on Friday. The business’s 50-day simple moving average is $70.24 and its 200 day simple moving average is $69.15. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The firm has a market capitalization of $28.26 billion, a PE ratio of 34.97, a PEG ratio of 1.43 and a beta of 1.49.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Robert W. Baird set a $87.00 price objective on DexCom in a research report on Friday, February 13th. Citigroup reiterated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Weiss Ratings downgraded shares of DexCom from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, February 18th. Sanford C. Bernstein restated an “outperform” rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 target price on shares of DexCom in a research note on Tuesday, December 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average price target of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.